Influence of Pneumococcal Vaccines and Respiratory Syncytial Virus on Alveolar Pneumonia, Israel
Daniel M. Weinberger
, Noga Givon-Lavi, Yonat Shemer-Avni, Jacob Bar-Ziv, Wladimir J. Alonso, David Greenberg, and Ron Dagan
Author affiliations: Yale School of Public Health, New Haven, Connecticut, USA (D.M. Weinberger); National Institutes of Health, Bethesda, Maryland, USA (D.M. Weinberger, W.J. Alonso); Soroka University Medical Center, Beer-Sheva, Israel (N. Givon-Lavi, Y. Shemer-Avni, D. Greenberg); Ben-Gurion University of the Negev, Beer-Sheva (N. Givon-Lavi, Y. Shemer-Avni, D. Greenberg, R. Dagan); Hadassah University Medical Center, Jerusalem, Israel (J. Bar-Ziv)
Main Article
Figure 2
Figure 2. . Observed (triangles) and expected (closed circles) change in RCAP incidence for each year compared with the 2004–05 through 2007–08 average, expressed as incidence rate ratios, southern Israel. Expected values were determined from a model fit to data from 2004–05 through 2010–11, with the 2011–12 values (open circles) extrapolated based on the observed virus activity.
Main Article
Page created: June 17, 2013
Page updated: June 17, 2013
Page reviewed: June 17, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.